Oblique Therapeutics. We focus on developing new antibody medicines in pain and aggressive-metastatic cancer.
Location: Sweden
Investors 3
| Date | Name | Website |
| - | Almi Inves... | almi.se |
| - | Midroc New... | midroc.se |
| - | Stockholms... | stoaf.se |
Mentions in press and media 14
| Date | Title | Description |
| 30.06.2026 | Oblique Therapeutics AB Announces Outcome of Rights Issue of SEK 14.1 Million | Oblique Therapeutics AB Announces Outcome of Rights Issue of SEK 14.1 Million Tue, Jun 30, 2026 08:50 CET Report this content Gothenburg, 26 June 2026 – Oblique Therapeutics AB (“Oblique” or the “Company”) today announces the outcome of the... |
| 08.05.2026 | Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor | Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor Fri, May 08, 2026 10:47 CET Report this content The recruitment represents a significant strategic addition to the company as it continu... |
| 22.10.2024 | Oblique Therapeutics announces that NaV 1.8 project is advancing to next stage | Oblique Therapeutics announces that NaV 1.8 project is advancing to next stage Tue, Oct 22, 2024 12:04 CET Report this content Stockholm, Sweden – October 22, 2024 – Oblique Therapeutics AB (“Oblique”) announces that the company's research ... |
| 23.08.2024 | The Future of Innovation: Partnerships and Events Shaping Tomorrow's Landscape | In the fast-paced world of biotechnology and advertising, collaboration and innovation are the lifeblood of progress. Two recent developments illustrate this dynamic: Oblique Therapeutics' partnership with Eli Lilly and Smartly's upcoming f... |
| 22.08.2024 | Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt[®] technology to generate antibodies to a high-value target | Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt[®] technology to generate antibodies to a high-value target Thu, Aug 22, 2024 12:59 CET Report this content Stockholm, Swede... |
| 18.06.2024 | Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers. | Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers. Tue, Jun 18, 2024 16:24 CET Report this content Stockholm, Sweden - 10 June... |
| 28.11.2023 | AAX Biotech forms strategic collaboration with Oblique Therapeutics for therapeutic antibody development | AAX Biotech forms strategic collaboration with Oblique Therapeutics for therapeutic antibody development Tue, Nov 28, 2023 08:00 CET Report this content Biotech company AAX Biotech, specializing in innovative technologies for improving anti... |
| 09.11.2022 | Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD . as Chief Executive Officer. | Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD . as Chief Executive Officer. Wed, Nov 09, 2022 08:39 CET Report this content Gothenburg, Sweden,9 November 2022 – Oblique Therapeutics AB (publ.),... |
| 14.01.2022 | Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology | Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology Fri, Jan 14, 2022 14:25 CET Press release – New Patent granted Gothenburg, Sweden, 14... |
| 15.11.2021 | Oblique Therapeutics is thrilled to strengthen its commercial teams to realize its ambitious goals | Oblique Therapeutics is thrilled to strengthen its commercial teams to realize its ambitious goals Mon, Nov 15, 2021 13:44 CET Press Release Gothenburg, Sweden, 15 November 2021 – Oblique Therapeutics, a biotech company focused on new antib... |
Show more